Lesson plan

Cangrelor

Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. It is authorized as a generic medication.

Back to article

Article summary

Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. It is authorized as a generic medication.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.